|
US2020024270A1
|
|
Compounds for treatment of cancer
|
|
US2019111010A1
|
|
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
|
US2018360805A1
|
|
Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
|
|
US2018353460A1
|
|
METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
|
|
US2018325858A1
|
|
METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
|
|
US2018118663A1
|
|
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
|
US2017209407A1
|
|
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
|
US2017137374A1
|
|
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
|
US2017166526A1
|
|
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
|
US2017029370A1
|
|
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
|
|
KR20170140291A
|
|
Selective androgen receptor dissociation (SARD) ligands and methods for their use
|
|
RU2724103C2
|
|
Selective androgen receptor destroying agents (sard) and methods of using thereof
|
|
US2017007567A1
|
|
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
|
US2017014401A1
|
|
Nuclear receptor binding agents
|
|
KR20190077607A
|
|
METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
|
|
AU2015227531A1
|
|
Compounds for treatment of cancer
|
|
US2016128968A1
|
|
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
|
US2016031797A1
|
|
Estrogen receptor ligands and methods of use thereof
|
|
AU2015202828A1
|
|
Compounds for treatment of cancer
|
|
US2015087712A1
|
|
Estrogen receptor ligands and methods of use thereof
|
